TheraBiogen Inc. (OTCBB: TRAB) is a manufacturer and distributor of homeopathic nasal sprays designed to combat cold, flu and allergy symptoms. Unlike other over-the-counter providers, like Par Pharmaceutical Company Inc. (NYSE: PRX) or Watson Pharmaceuticals Inc. (NYSE: WPI), the company’s products have a very efficient nasal drug delivery method that has no direct competitors.
TheraBiogen, Inc. (OTC.BB: TRAB) is pleased to announce it is in agreement with Walgreens for distribution nationally in all their approximately 7500 locations for the 2011-2012 cold and flu season.
TheraBiogen has been selling TheraMax® Cold & Flu Relief and TheraMax® Allergy Relief since the beginning of the 2010 Fall season. Consumers nationwide have embraced the new products in their initial launch. Kelly Hickel, CEO of TheraBiogen, Inc., said, “We are very excited that Walgreens, the number one drug retailer in the world, will make TheraMax® Cold & Flu Relief available to consumers in all their locations nationally. As we expand distribution, we expect to see the same continued support from consumers that we have seen since our launch last fall.”
About TheraBiogen, Inc.
TheraBiogen, Inc. is the manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com or our Facebook page at facebook.com/theramaxnasalspray.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company’s most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules.